BEGIN:VCALENDAR VERSION:2.0 PRODID:-//132.216.98.100//NONSGML kigkonsult.se iCalcreator 2.20.4// BEGIN:VEVENT UID:20260122T000114EST-9425zb1mju@132.216.98.100 DTSTAMP:20260122T050114Z DESCRIPTION:This workshop is organized by Dr. Pedro Rosa-Neto\, MD\, PhD\, from The Douglas Research Centre\, Â鶹´«Ã½ÍøÕ¾\, and The Neuro. The event will focus on discussing the indications\, prescription\, and manage ment of adverse events associated with anti-amyloid therapy using monoclon al antibodies.\n\nThe workshop will provide valuable insights into the lat est treatment strategies and guidelines\, aiming to equip healthcare resea rchers and professionals with the necessary tools to manage and prescribe anti-amyloid therapies effectively. Additionally\, it will help enhance th e knowledge and skills required to handle adverse effects associated with these treatments.\n\n\nClick here to register.\n\nFor virtual attendance\, click here\n\n\nSuzanne Schindler\, MD\, PhD\n\nDepartment of Neurology\, Washington University School of Medicine\n\nTalk: Diagnosis and Treatment of Early  Symptomatic Alzheimer’s Disease\n\nAbstract: The early and accu rate diagnosis of Alzheimer’s disease in patients with cognitive impairmen t is more important than ever now that disease-modifying treatments are be coming available. This lecture will describe how to diagnose early symptom atic Alzheimer’s disease by integrating clinical information with biomarke r tests. The advantages and disadvantages of amyloid PET\, CSF biomarkers\ , and new blood biomarkers will be reviewed with a focus on clinical blood biomarker tests. Further\, the identification\, treatment\, and monitorin g of appropriate patients for anti-amyloid treatments will be discussed. R eal-world data and experience with biomarker testing and anti-amyloid trea tments from the Washington University Memory Diagnostic Center will be det ailed.\n\nBio: Dr. Schindler is a clinical neurologist and dementia specia list. Dr. Schindler is also trained as a neuroscientist and her overall re search goal is to improve the diagnosis and treatment of Alzheimer disease and related disorders. Dr. Schindler's recent research has been on develo ping and testing fluid (blood and CSF) biomarkers for Alzheimer disease an d is currently working towards predicting if and when cognitively normal i ndividuals will develop symptoms of Alzheimer disease dementia based on a single blood or CSF sample and individual characteristics.\n\nAlireza Atri \, MD\, PhD\n\nDepartment of Neurology\, Harvard Medical School\n\nTalk: A myloid Related Imaging Abnormalities (ARIA)\n\nAbstract: Amyloid-related i maging abnormalities (ARIA) are imaging changes associated with beta-amylo id plaque-lowering monoclonal antibodies for treatment of early clinical s tage Alzheimer’s disease (AD) that can be observed on magnetic resonance i maging (MRI). ARIA-E refers to vasogenic edema in the brain parenchyma and /or leptomeningeal/subpial sulcal effusion\; ARIA-H refers to hemosiderin deposits including cerebral microhemorrhage and localized superficial side rosis. ARIA can result in symptomatic adverse events and poor outcomes if not detected\, monitored and managed through timely\, coordinated and appr opriate practices. A spectrum of radiographic and clinical presentations o f ARIA have been observed and with the emerging availability of lecanemab and donanemab there is an important need for ARIA awareness\, coordination and proficiency among a diversity of clinicians and practice settings. Th is presentation will discuss current understanding and learnings about the nature and factors associated with ARIA\; the varied radiographic and cli nical presentations of ARIA\; and detection\, monitoring and management st rategies for that can increase knowledge and proficiency for clinicians an d researchers to care for persons treated with AD amyloid plaque-lowering monoclonal antibodies.\n\nBio: Dr. Atri is an internationally renowned cog nitive neurologist\, neuroscientist\, clinical researcher and educator in the fields of Alzheimer’s disease (AD) and Related Dementias (ADRD).  Dr. Atri is Chief Medical Officer of Banner Research (Banner Alzheimer’s Insti tutes\, Phoenix and Tucson) and Director of the Banner Sun Health Research Institute (Sun City)\, AZ. He serves as Associate Director of the NIA/NIH -funded Arizona Alzheimer’s Disease Research Center (AZ-ADRC)\, Leader of the AZ-ADRC Clinical Core\, and Co-Leader of the Biomarker Core\; and on t he part-time faculty at Brigham and Women’s Hospital (BWH) and Harvard Med ical School (HMS)\, Boston\, MA\, USA.  He specializes in diagnostics\, ex perimental therapeutics and care of individuals with cognitive disorders a nd dementia\, particularly individuals with early-stage impairments and ea rly-onset AD/ADRD. Dr. Atri holds advanced degrees from the University of CA\, Los Angeles (UCLA Ph.D. Biomathematics)\, University of CA\, San Fran cisco (UCSF M.D.) and Harvard Medical School (M.M.Sc.). He completed inter nship (medicine)/residency(neurology) at the Harvard Massachusetts General (MGH)-Brigham programs\; post-graduate training and clinical/research fel lowships at MGH/HMS (Cognitive Neurology & Dementias)\, Boston University (Cognitive & Computational Neuroscience) and Massachusetts Institute of Te chnology (MIT Experimental Therapeutics)\; and served on the faculty of MG H for 15 years. His research and education focus on early detection\, risk reduction\, experimental therapeutics\, global impact and best care pract ices in AD/ADRD. Dr. Atri is a widely published and grant-funded researche r and clinician-educator who serves in a leadership capacity on several gl obal AD/ADRD experimental therapeutics and biomarker programs\, clinical t rials consortia\, and ADRD-related workgroups\, including as co-chair of t he U.S. Alzheimer’s Association national clinical practice guidelines work group on the evaluation of suspected cognitive impairment and AD/ADRD\, an d as chair of the Alzheimer’s Disease International (ADI) Medical Scientif ic Advisory Panel. \n\nSerge Gauthier\, MD\n\nÂ鶹´«Ã½ÍøÕ¾ Dementia Education Pr ogram\, Department of Neurology & Neurosurgery\, Department of Psychiatry\ , Â鶹´«Ã½ÍøÕ¾\n\nTalk: Canada’s Preparedness for the Use of Biomarke rs and Disease-Modifying Drugs\n\nBio: Dr. Serge Gauthier is Academic Co-L ead of the Dementia Education Program and Professor Emeritus in the Depart ment of Neurology & Neurosurgery and Department of Psychiatry at Â鶹´«Ã½ÍøÕ¾ Un iversity. He is a clinical neurologist specializing in the development of new tools for diagnosis and treatments for people living with Alzheimer’s disease. He completed his medical studies at the Université de Montréal\, his neurology training at Â鶹´«Ã½ÍøÕ¾\, and a research Fellowship at Prof. Theodore L. Sourkes laboratory\, Allen Memorial Institute\, Montrea l. Dr. Gauthier was a clinical investigator and staff neurologist at the M ontreal Neurological Hospital and Institute (The Neuro) from 1976-1986. He was the Director of the Â鶹´«Ã½ÍøÕ¾ Research Centre for Studies in Aging (MCSA) from 1986 to 1997\, and Director of the Alzheimer Disease and Related Disorders Research Unit of the MCSA until 2021. He was also a Sen ior Scientist of the Canadian Institutes of Health Research and Developmen t (CIHR-RxD) from 1997 to 2007.\n\n \n\n\n \n Programme\n Sponsors\n Organizin g Committee\n \n\n \n Programme\n\n Tuesday\, December 3\, 2024\n\n \n \n \n 1:00 \n \n Welcome & Opening Remarks\n\n Pedro Rosa-Neto\, MD\, PhD\, The Douglas Research Centre\, Â鶹´«Ã½ÍøÕ¾\n \n \n \n  \n Moderator: Serge Gauthier\, MD\, Â鶹´«Ã½ÍøÕ¾ Dementia Education Program\, Department of Neurology & Neurosu rgery\, Department of Psychiatry\, Â鶹´«Ã½ÍøÕ¾\n \n \n 1:15\n \n Killam S eminar courtesy of The Killam Trusts\n\n Diagnosis and Treatment of Early S ymptomatic Alzheimer’s Disease\n\n Suzanne Schindler\, MD\, PhD\, Knight Al zheimer Disease Research Center\, Washington University School of Medicine in St. Louis\n \n \n \n 2:15\n Refreshment Pause\n \n \n 2:45\n \n Amyloid Related Imaging Abnormalities (ARIA)\n\n Alireza Atri\, MD\, PhD\, Banner Sun Healt h Research Institute\, Harvard Medical School\n \n \n \n 3:45\n \n Canada’s Prep aredness for the Use of Biomarkers and Disease-Modifying Drugs\n\n Serge Ga uthier\, MD\, Â鶹´«Ã½ÍøÕ¾ Dementia Education Program\, Department of Neurology & Neurosurgery\, Department of Psychiatry\, Â鶹´«Ã½ÍøÕ¾\n \n \n \n 4:05 \n Panel Q&A\n \n \n 4:35\n \n Closing Remarks\n\n Pedro Rosa-Neto\, MD\, PhD\, T he Douglas Research Centre\, Â鶹´«Ã½ÍøÕ¾\n \n \n \n 4:45\n Cocktail & Net working\n \n \n \n \n\n \n Sponsors\n\n \n\n \n \n\n \n Organizing Committee\n\n Pedro Rosa-Neto\n Director\, Translational Neuroimaging Laboratory\, Douglas Res earch Centre\n\n Debbie Rashcovsky\n Neuro Events Team Lead\n \n\n DTSTART:20241203T180000Z DTEND:20241203T213000Z LOCATION:de Grandpre Communications Centre\, Montreal Neurological Institut e\, CA\, QC\, Montreal\, H3A 2B4\, 3801 rue University SUMMARY:Management of Disease Modifying Interventions in Alzheimer's URL:/neuro/channels/event/management-disease-modifying -interventions-alzheimers-359564 END:VEVENT END:VCALENDAR